{"filing":{"accession_number":"0001129928-26-000045","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"oncy-20260720.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000045/oncy-20260720.htm"},"events":[{"id":18680,"run_id":16798,"accession_number":"0001129928-26-000045","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Oncolytics announced that the FDA granted Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for treating advanced squamous cell carcinoma of the anal canal. This is a significant regulatory milestone that accelerates development and review timelines, represents the third Fast Track designation in gastrointestinal cancers, and addresses an estimated $1 billion market with no approved therapies for second-line patients. While this is a positive regulatory development rather than a traditional operational event, it is a material strategic and regulatory milestone that would affect investor assessment of the company's development trajectory and de-risking of its pipeline.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17560,"accession_number":"0001129928-26-000045","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Oncolytics announced that the FDA granted Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for treating advanced squamous cell carcinoma of the anal canal. This is a significant regulatory milestone that accelerates development and review timelines, represents the third Fast Track designation in gastrointestinal cancers, and addresses an estimated $1 billion market with no approved therapies for second-line patients. While this is a positive regulatory development rather than a traditional operational event, it is a material strategic and regulatory milestone that would affect investor assessment of the company's development trajectory and de-risking of its pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:05:45.383202+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17560,"accession_number":"0001129928-26-000045","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Oncolytics announced that the FDA granted Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for treating advanced squamous cell carcinoma of the anal canal. This is a significant regulatory milestone that accelerates development and review timelines, represents the third Fast Track designation in gastrointestinal cancers, and addresses an estimated $1 billion market with no approved therapies for second-line patients. While this is a positive regulatory development rather than a traditional operational event, it is a material strategic and regulatory milestone that would affect investor assessment of the company's development trajectory and de-risking of its pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:05:45.383202+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-07-20"}]}